Ausgabe 1/2019
Inhalt (23 Artikel)
Awakening the “guardian of genome”: reactivation of mutant p53
Akshay Binayke, Sarthak Mishra, Prabhat Suman, Suman Das, Harish Chander
Autophagy and its potent modulators from phytochemicals in cancer treatment
Chao-Yue Sun, Qian-Yu Zhang, Guang-Juan Zheng, Bing Feng
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters
Laure Deyme, Dominique Barbolosi, Florence Gattacceca
Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET
Susumu Hijioka, Keiichiro Sakuma, Masahiro Aoki, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Kazuo Hara, Yasushi Yatabe
Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy
Jacob Nersting, Stine Nygaard Nielsen, Kathrine Grell, Maria Paerregaard, Jonas Abrahamsson, Bendik Lund, Olafur Gisli Jonsson, Kaie Pruunsild, Goda Vaitkeviciene, Jukka Kanerva, Kjeld Schmiegelow
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients
Brittney R. Starling, Parag Kumar, Andrew T. Lucas, David Barrow, Laura Farnan, Laura Hendrix, Hugh Giovinazzo, Gina Song, Paola Gehrig, Jeannette T. Bensen, William C. Zamboni
Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis
Yu Bai, Hai-wei Wu, Yan-hua Zhang
Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats
Priyanka Arora, Courtney Huff Adams, Gary Gudelsky, Biplab DasGupta, Pankaj B. Desai
Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers
Nathalie Rioux, Amy Kim, Darrell Nix, Todd Bowser, Markus Warmuth, Peter G. Smith, Joanne Schindler
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Kristina Lindemann, Philip J. Beale, Emma Rossi, Jeff C. Goh, Michelle M. Vaughan, Meaghan E. Tenney, Julie K. Martyn, Dirkje Sommeijer, Jose L. Iglesias, Gabriel Kremmidiotis, Jeremy Simpson, Elizabeth Doolin, Tina C. Lavranos, Annabell Leske, Anneso S. Veillard, David Espinoza, Martin R. Stockler, Danny Rischin
Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms
Akimitsu Maeda, Kei Irie, Hitoshi Ando, Ayako Hasegawa, Hiroya Taniguchi, Shigenori Kadowaki, Kei Muro, Masahiro Tajika, Masahiro Aoki, Kazuhide Inaguma, Masaki Kajita, Akio Fujimura, Shoji Fukushima
Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Osman Köstek, Muhammet Bekir Hacıoğlu, Abdullah Sakin, Tarık Demir, Murat Sarı, Ozlem Ozkul, Murat Araz, Aysun Fatma Doğan, Nazım Can Demircan, Sernaz Uzunoğlu, İrfan Çiçin, Bülent Erdoğan
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
Hironori Fujii, Yunami Yamada, Daichi Watanabe, Nobuhisa Matsuhashi, Takao Takahashi, Kazuhiro Yoshida, Akio Suzuki
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
Ece Esin, B. Oksuzoglu, A. Bilici, I. Cicin, O. Kostek, M. A. Kaplan, S. Aksoy, B. Y. Aktas, O. Ozdemir, A. Alacacioglu, D. Cabuk, A. T. Sumbul, A. Sakin, S. Paydas, E. Yetisir, O. Er, T. Korkmaz, N. Yildirim, T. Sakalar, H. Demir, M. Artac, M. Karaagac, H. Harputluoglu, E. Bilen, E. Erdur, S. Degirmencioglu, A. Aliyev, T. Cil, P. Olgun, G. Basaran, O. Gumusay, A. Demir, E. Tanrikulu, P. F. Yumuk, Inanc Imamoglu, B. Oyan, B. Cetin, V. Haksoyler, N. Karadurmus, I. Erturk, T. Evrensel, H. Yilmaz, I. Beypinar, M. Kocer, K. N. Pilanci, M. Seker, Y. Urun, N. Yildirim, T. Eren, U. Demirci, B. Oksuzoglu, A. Bilici, O. Kostek, I. Cicin, M. A. Kaplan, B. Y. Aktas, S. Aksoy, O. Ozdemir, A. Alacacioglu, D. Cabuk, A. T. Sumbul, A. Sakin, E. Yetisir, S. Paydas, O. Er, T. Korkmaz, N. Yildirim, T. Sakalar, H. Demir, M. Karaagac, M. Artac, H. Harputluoglu, E. Bilen, S. Degirmencioglu, A. Aliyev, P. Olgun, T. Cil, G. Basaran, O. Gumusay, A. Demir, E. Tanrikulu, P. F. Yumuk, Inanc Imamoglu, B. Uluc Oyan, B. Cetin, V. Haksoyler, N. Karadurmus, I. Erturk, H. Yilmaz, T. Evrensel, Beypinar, Kocer, K. N. Pilanci, M. Seker, Y. Urun, N. Yildirim, T. Eren, U. Demirci
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial
Koji Murono, Hiroshi Nagata, Kazuhiro Ishimaru, Shigenobu Emoto, Manabu Kaneko, Masaya Hiyoshi, Kazuhito Sasaki, Kensuke Otani, Yasutaka Shuno, Takeshi Nishikawa, Toshiaki Tanaka, Keisuke Hata, Kazushige Kawai, Hiroaki Nozawa, Kei Muro, Soichiro Ishihara
Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA)
Nathalie Rioux, Sherri Smith, Manav Korpal, Morgan O’Shea, Sudeep Prajapati, Guo Zhu Zheng, Markus Warmuth, Peter G. Smith
A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer
Yasushi Sato, Tamotsu Sagawa, Hiroyuki Ohnuma, Masahiro Hirakawa, Yasuo Takahashi, Kyoko Hamaguchi, Koshi Fujikawa, Takayuki Nobuoka, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Ichiro Takemasa, Tetsuji Takayama
Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
I. Kümler, P. Grundtvig Sørensen, J. Palshof, E. Høgdall, W. Skovrider-Ruminski, S. Theile, A. Fullerton, P. G. Nielsen, B. Vittrup Jensen, D. L. Nielsen
Steroidal dimer by001 inhibits proliferation and migration of esophageal cancer cells via multiple mechanisms
Sai-Qi Wang, Kai-Rui Zhou, Xiao-Li Shi, Hui-Fang Lv, Liang-Yu Bie, Wei-Jie Zhao, Xiao-Bing Chen
Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
Robin L. Jones, Gary Mo, John R. Baldwin, Patrick M. Peterson, Robert L. Ilaria Jr., Ilaria Conti, Damien M. Cronier, William D. Tap
Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study
Kazuo Sato, Yasuharu Toyoshima, Shiho Moriyama, Yutaka Endo, Tetsuhide Ito, Emiko Ohki
Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients
W. Venus So, Tai-Hsien Ou Yang, Xing Yang, Jianguo Zhi
Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice
Soumaya Labidi, Nesrine Mejri, Houda El Benna, Mehdi Afrit, Sarra Lakhdher, Hamouda Boussen